The management of febrile neutropenia in the posaconazole era: a new challenge?


Over the years, the spectrum of patients at risk for invasive fungal disease (IFDs) has expanded. This is a result of the aging of the general population, progress in supportive care allowing clinicians to perform a higher number of aggressive and curative treatments, the introduction of new drugs in clinical practice (i.e. monoclonal antibodies… (More)
DOI: 10.3324/haematol.2012.062166


  • Presentations referencing similar topics